Los Angeles Capital Management
DSGN icon

Los Angeles Capital Management’s Design Therapeutics DSGN Stock Holding History

Los Angeles Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,735
Closed -$42.9K – 1406
2025
Q2 		$42.9K Buy
+12,735
New +$47.7K ﹤0.01% 1316

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Los Angeles Capital Management's DSGN Position: Q3 2025 in Review

Los Angeles Capital Management sold out of Design Therapeutics (DSGN) in Q3 2025, closing a stake of 12,735 shares — an estimated $42.9K sold.

Los Angeles Capital Management first reported a position in DSGN in Q2 2025 and held it in 1 quarter. The position peaked at $42.9K in Q2 2025. 95 funds tracked by Wall St. Rank hold DSGN as of Q3 2025.

  • Los Angeles Capital Management reported no remaining Design Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Los Angeles Capital Management sold 12,735 Design Therapeutics shares in Q3 2025, an estimated $42.9K.
  • Los Angeles Capital Management first reported a position in Design Therapeutics in Q2 2025 and held it in 1 quarter.
  • Los Angeles Capital Management's Design Therapeutics position peaked at $42.9K in Q2 2025.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2025.

Based on Los Angeles Capital Management's 13F filing for Q3 2025, filed 20 Oct 2025.